Ankündigung • Oct 22

Calidi Biotherapeutics, Inc. Announces Establishment of Scientific Advisory Board

Calidi Biotherapeutics, Inc. announced the formation of its Scientific Advisory Board (SAB) comprised of leading industry and academic researchers in with deep expertise in drug development. The SAB will work with Calidi to further develop its RedTail platform and advance CLD-401 into the clinic. RedTail is Calidi’s groundbreaking approach to genetic medicines that utilizes an enveloped form of vaccinia virus genetically engineered to overexpress CD55 and avoid immune clearance, allowing for systemic delivery and targeting of genetic medicine payload(s) to sites of disease. Founding members of Calidi’s new Scientific Advisory Board are: Mace L. Rothenberg, MD, FACP, is a physician-executive with more than 30 years of experience in drug development, translational research, and risk-benefit assessment. Mace Rothenberg, MD is President and Executive Director of the Museum of Medicine and Biomedical Discovery. His nearly 40-year career has spanned government, academia, industry, and the not-for-profit sector. Prior to his current role, Dr. Rothenberg was Chief Medical Officer of Pfizer from 2019 to 2021, during which time the company developed and received Emergency Use Authorization for Comirnity, its Covid-19 vaccine. Prior to that role, Mace was Chief Development Officer/Head of Clinical Development & Medical Affairs for Pfizer Oncology. Over the course of 10 years in that role, his organization developed and obtained regulatory approval for 11 new cancer medicines. Prior to joining Pfizer, Dr. Rothenberg was Professor of Medicine at the University of Texas Health Science Center at San Antonio (1991-1998) and Vanderbilt University (1998-2008). Dr. Rothenberg began his career as Special Assistant to the Director, Division of Cancer Treatment at the National Cancer Institute in Bethesda, Maryland (1988-1991). Dr. Rothenberg received his BA magna cum laude from the University of Pennsylvania, his MD from New York University, his post-graduate training in Internal Medicine at Vanderbilt, and his medical oncology training at the National Cancer Institute. He is a Fellow of the American College of Physicians, the American Society of Clinical Oncology, and the New York Academy of Medicine. Mace serves as a director of Tango Therapeutics, Surrozen, and Aulos Biosciences. He is chairman of the board of Chiara Biosciences. He also serves on the board of several non-profit organizations including the Pancreatic Cancer Action Network (PanCAN), NashBio, and the Councils of Advisors for the Vanderbilt-Ingram Cancer Center and Vanderbilt University School of Medicine Basic Sciences. Dmitriy Zamarin MD, PhD, is a medical oncologist and Section Head of Gynecologic Medical Oncology and Co-Director of the Center of Excellence for Gynecologic Cancer and a world leader in virotherapy for cancer. Dr. Dmitriy Zamarin is a member of the Icahn Genomics Institute and the Precision Immunology Institute at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. Prior to Mount Sinai, Dmitriy spent a decade as a faculty and Translational Research Director in Gynecologic Medical Oncology at the Memorial Sloan Kettering Cancer Center before transitioning to his current role in September of 2023.Dr. Zamarin has served as a principal investigator and a translational chair on multiple institutional and cooperative group clinical trials exploring novel immunotherapy combinations in gynecologic cancers and other solid tumors and serves as the translational research co-chair on the NRG Oncology Cervical Cancer committee. In the laboratory, his research uses mouse models to explore the mechanisms of tumor-immune system interactions and to develop novel therapeutics, with particular focus on oncolytic viruses, vaccines, and targeted therapies. For his work Dr. Zamarin has received awards and funding from multiple organizations including Damon Runyon Foundation, Ovarian Cancer Research Alliance, Department of Defense, and R01 grants from the National Cancer Institute. John Wrangle, MD, MPH, is a thoracic oncologist and scientist and an expert in translation immunotherapy with extensive experience around IL-15-based treatment in metastatic cancerDr. John M. Wrangle is Associate Professor of Hematology/Oncology at the Medical University of South Carolina (MUSC) and holds the SmartState Burtschy Family Distinguished Endowed Chair in Lung Cancer Research. He is a thoracic medical oncologist focused on developing novel immunotherapy and gene-based strategies for non–small cell lung cancer and other thoracic malignancies. Dr. Wrangle completed his internship and residency in Internal Medicine at Emory University, followed by fellowship training in Hematology and Medical Oncology at Johns Hopkins University. He is board certified in Internal Medicine and Medical Oncology. In his clinical-translational work, Dr. Wrangle led the Phase 2 trial combining PD-1 checkpoint blockade with the IL-15 superagonist ALT-803 (now known as N-803), demonstrating tumor responses in patients with non–small cell lung cancer (Lancet Oncology, Wrangle et al. 2018).Dr. Wrangle also leads efforts to translate lab discoveries into clinical trials, with recent support from the Department of Defense Lung Cancer Research Program to pursue gene-therapy–inspired cancer strategies. He is deeply committed to reducing disparities in lung cancer care in underserved populations in South Carolina, aiming to bring cutting-edge therapies to patients outside major academic centers. David T. Curiel, MD, PhD is a world leader in cancer immunotherapy and cancer virotherapy.Dr. David T. Curiel is a tenured Professor in the Cancer Biology Division of the Department of Radiation Oncology at Washington University School of Medicine in St. Louis. Dr. Curiel earned his MD from Emory University in 1982 and subsequently completed his internship and residency in internal medicine at Emory. Dr. Curiel’s research has centered on engineering viral vectors for gene therapy, virotherapy, and vaccine development, with an emphasis on improving tumor targeting, immune evasion, and durable therapeutic effects. His oncolytic virus efforts include translation toward clinical trials in glioblastoma, among other cancers. During the COVID-19 pandemic, Dr. Curiel collaborated in developing a nasal vaccine delivered via adenovirus that elicits mucosal and systemic immunity; this vaccine has been licensed for development and has achieved regulatory authorizations in India. He has been recognized with innovation awards for this work. In recognition of his contributions to viral vector–based therapeutics and translation, Dr. Curiel was elected a Fellow of the National Academy of Inventors. He is also a co-founder of biotech companies (e.g. DNAtrix, Precision Virologics) focused on translating gene- and virus-based therapies to the clinic.

Biotechs Wachstum der Industrie	17.04%
Wachstumsrate der Einnahmen	n/a
Eigenkapitalrendite	-558.83%
Netto-Marge	n/a
Letzte Ertragsaktualisierung	30 Jun 2026

Datum	Gewinn	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Jun 26	-23	8	10
31 Mar 26	-25	9	10
31 Dec 25	-26	11	10
30 Sep 25	-26	11	9
30 Jun 25	-20	11	9
31 Mar 25	-22	12	9
31 Dec 24	-24	13	9
30 Sep 24	-28	17	11
30 Jun 24	-25	17	12
31 Mar 24	-30	17	13
31 Dec 23	-29	16	13
30 Sep 23	-29	17	11
30 Jun 23	-32	16	10
31 Mar 23	-24	15	8
31 Dec 22	-25	16	7
30 Sep 22	-21	11	6
31 Dec 21	-11	6	4

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/08/18 09:32
Aktienkurs zum Tagesende	2026/08/18 00:00
Gewinne	2026/06/30
Jährliche Einnahmen	2025/12/31

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

Analyst	Einrichtung
Joel Beatty	Baird
Aydin Huseynov	Ladenburg Thalmann & Company

Calidi Biotherapeutics Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Calidi Biotherapeutics Presents New Data On CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 At The T-Cell Engager Therapeutic Summit

Calidi Biotherapeutics, Inc. Announces Appointment of Corsee Sanders to Board of Directors and Member of the Audit Committee, Effective June 17, 2026

Calidi Biotherapeutics, Inc. Receives Positive Pre-Ind Feedback From US FDA For CLD-401 And Advances Ind-Enabling Studies Towards First-In-Human Study

Calidi Biotherapeutics Presents New Data on Cld-401 At the Aacr Annual Meeting

Calidi Biotherapeutics, Inc., Annual General Meeting, Jun 12, 2026

Calidi Biotherapeutics to Presents New Data on Differentiated Approach to in Situ T-Cell Engagers Including New Candidate Targeting Trop-2

Calidi Biotherapeutics Presents Innovative And Scalable Manufacturing Process For CLD-401

New major risk - Share price stability

Calidi Biotherapeutics, Inc. has completed a Composite Units Offering in the amount of $10.519632 million.

Calidi Biotherapeutics, Inc. Presents Data on its New Approach to Bispecific T-Cell Engagers Using its RedTail Platform at the 2026 AACR-IO Conference

Calidi Biotherapeutics, Inc. to Present on Its New Approach to Bispecific T-Cell Engagers Using Its Redtail Platform in A Late-Breaking Abstract At the 2026 Aacr-Io Conference

High number of new and inexperienced directors

Calidi Biotherapeutics, Inc. Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting

Calidi Biotherapeutics, Inc. Announces Establishment of Scientific Advisory Board

New major risk - Market cap size

Calidi Biotherapeutics, Inc. has completed a Composite Units Offering in the amount of $6 million.

Calidi Biotherapeutics, Inc. Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma

New major risk - Market cap size

Calidi Biotherapeutics Inc. Presents Systemic Oncolytic Platform with Cd55-Enhanced Expression and Il-15 Superagonist Payload At Asco Annual Meeting

New major risk - Financial position

Calidi Biotherapeutics, Inc., Annual General Meeting, Jul 01, 2025

Calidi Biotherapeutics Inc. Announces IL15 Superagonist as First Payload to Be Delivered by Systemic Antitumor Virotherapy Platform At AACR Annual Meeting

Calidi Biotherapeutics Inc. Announces Chief Executive Officer Changes, Effective April 22, 2025

Calidi Biotherapeutics, Inc. Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors

Calidi Biotherapeutics Inc. Appoints Guy Travis Clifton as Chief Medical Officer

Calidi Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $3.931722 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.931722 million.

Calidi Biotherapeutics and City of Hope Provide Update on A Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma

Calidi Biotherapeutics Announces Demonstrated Ability to Deliver Transient Gene Therapy (Payload) to Tumors Using Systemic Platform

Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose Cld-101 Trial in Patients with Newly Diagnosed High Grade Glioma At Northwestern University Hospital

Calidi Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.25 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics Inc. Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.499999 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics Inc. to Present Data Supporting RTNova at Upcoming Scientific Conferences

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.

Calidi Biotherapeutics, Inc. Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma

Calidi Biotherapeutics, Inc., Annual General Meeting, Sep 20, 2024

Calidi Biotherapeutics, Inc. Announces George Ng Decision to Allow the Term of His Position as a Director of the Board to Expire and to Not Seek Re-Election to the Board

Calidi Biotherapeutics, Inc. Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Calidi Biotherapeutics, Inc. Appoints George E. Peoples to Its Board of Directors

Independent Director exercised options to buy US$106k worth of stock.

Calidi Biotherapeutics Presents Cld-101 Phase 1 Trial Update and Preclinical Data Highlighting Rtnova and Cld-201 At 2024 Asco Annual Meeting

New major risk - Financial position

New major risk - Market cap size

New major risk - Revenue and earnings growth

Calidi Biotherapeutics, Inc. announced that it has received $3.5 million in funding

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics, Inc. Announces Scientific and Medical Advisory Board Appointments

Less than half of directors are independent

Calidi Biotherapeutics Announces Directorate Changes

Calidi Biotherapeutics, Inc. Announces the Resignation of Alfonso Zulueta as A Director, Including His Position on Audit Committee of the Board

New major risk - Financial position

New major risk - Shareholder dilution

Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Calidi Biotherapeutics, Inc. Announces Key Leadership Promotions and New Board Appointment

Calidi Biotherapeutics, Inc. Enters into an Employment Agreement with Andrew Jackson to Serve as Chief Financial Officer

Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Interim Chief Financial Officer

Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Chief Accounting Officer

Less than half of directors are independent

Calidi Biotherapeutics, Inc. Appoints Alan R. Stewart as the Class I Director

Calidi Biotherapeutics, Inc. Announces the Resignation of Dr. Heehyoung Lee, Including All Her Positions on the Committees of the Board

Calidi Biotherapeutics, Inc. executed a term sheet to acquire First Light Acquisition Group, Inc. (NYSEAM:FLAG) from group of sellers in a reverse merger transaction.

Aufschlüsselung der Einnahmen und Ausgaben

Gewinn- und Umsatzhistorie

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Eigenkapitalrendite

Kapitalrendite

Rendite auf das eingesetzte Kapital

Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren

Unternehmensanalyse und Finanzdaten Status

Datenquellen